Cas:31036-80-3 Lofexidine manufacturer & supplier

Chemical Name:Lofexidine

CAS.NO:31036-80-3

Synonyms:MFCD00865915;2-{1-[(2,6-dichlorophenyl)oxy]ethyl}-4,5-dihydro-1H-imidazole;2-(a-(2,6-dichlorophenoxy)ethyl)2-imidazoline;Lofexidinum [INN-Latin];Lofexidina;1H-Imidazole, 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-;Britlofex;Lofexidine;(±)-2-[1-(2,6-Dichlorophenoxy)ethyl]-2-imidazoline;Lofexidinum;Lofexidine [INN:BAN];Lofexidina [INN-Spanish];2-[1-(2,6-dichlorophenoxy)ethyl]-2-imidazoline;UNII:UI82K0T627;(-)-2-[1-(2,6-dichlorophenoxy)-ethyl]-1,3-diazacyclopent-2-ene;2-[1-(2,6-Dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole;rac-2-[1-(2,6-dichlorophenoxy)ethyl]-1,3-diazacyclopent-2-ene

Molecular Formula:C₁₁H₁₂Cl₂N₂O

Molecular Weight:259.132

HS Code:

Physical and Chemical Properties:

Melting point:215-225 °C

Boiling point:421.5±35.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.611

PSA:33.62000

Exact Mass:258.032654

LogP:3.59

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like MFCD00865915 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,rac-2-[1-(2,6-dichlorophenoxy)ethyl]-1,3-diazacyclopent-2-ene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,rac-2-[1-(2,6-dichlorophenoxy)ethyl]-1,3-diazacyclopent-2-ene Use and application,2-(a-(2,6-dichlorophenoxy)ethyl)2-imidazoline technical grade,usp/ep/jp grade.

Related News: Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: ��Within the top 20 global companies that spent the most on R&D in 2018, the top spender �C despite having the second smallest annual revenue of the group at $15.28 billion �C is Celgene, whose R&D spend was equal to 37% of its annual revenue. Lofexidine manufacturer Professionally produce and submit DMF files, and supplement data at any time during the patent challenge of formulation companies. Lofexidine supplier Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: ��Within the top 20 global companies that spent the most on R&D in 2018, the top spender �C despite having the second smallest annual revenue of the group at $15.28 billion �C is Celgene, whose R&D spend was equal to 37% of its annual revenue. Lofexidine vendor Judging from the geographical distribution of enterprises, the largest distribution of API companies is Jiangsu and Zhejiang, with more than 300 enterprises; followed by Shandong, Sichuan and Hubei. Lofexidine factory Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037.